Value of high-sensitivity C-reactive protein assays in predicting atrial fibrillation recurrence: A systematic review and meta-analysis

BMJ Open

Volumn 4, Issue 2, 2014, Pages

  Yo, Chia Hung ^a   Lee, Si Huei ^b   Chang, Shy Shin ^c,d   Lee, Matthew Chien Hung ^e   Lee, Chien Chang ^f,g  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e Medical Wisdom Consultants   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

CARDIOVERSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HEART ATRIUM FIBRILLATION; HUMAN; INFORMATION RETRIEVAL; MEASUREMENT; PROTEIN DETERMINATION; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ATRIAL FIBRILLATION; BLOOD; META ANALYSIS; METABOLISM; PREDICTIVE VALUE; RECURRENT DISEASE;

ATRIAL FIBRILLATION; C-REACTIVE PROTEIN; ELECTRIC COUNTERSHOCK; HUMANS; PREDICTIVE VALUE OF TESTS; RECURRENCE;

EID: 84896881535     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004418     Document Type: Review

References (41)

1. Fabbri G, Maggioni AP. A review of the epidemiological profile of patients with atrial fibrillation and heart failure. Expert Rev Cardiovasc Ther 2012;10:1133-40.
2. Menezes AR, Lavie CJ, DiNicolantonio JJ, et al. Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc 2013;88:394-409.
3. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:1935-44.
4. Manlucu J, Brancato S, Lane C, et al. Contemporary approaches to persistent atrial fibrillation. Expert Rev Cardiovasc Ther 2012;10:1421-35.
5. Disertori M, Lombardi F, Barlera S, et al. Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. Am Heart J 2011;162:382-9.
6. Letsas KP, Weber R, Burkle G, et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace 2009;11:158-63.
7. Liu T, Li L, Korantzopoulos P, et al. Meta-analysis of association between C-reactive protein and immediate success of electrical cardioversion in persistent atrial fibrillation. Am J Cardiol 2008;101:1749-52.
8. Roberts WL, Sedrick R, Moulton L, et al. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 2000;46:461-8. (Pubitemid 30210716)
9. Celebi OO, Celebi S, Canbay A, et al. The effect of sinus rhythm restoration on high-sensitivity C-reactive protein levels and their association with long-term atrial fibrillation recurrence after electrical cardioversion. Cardiology 2011;118:168-74.
10. Barassi A, Pezzilli R, Morselli-Labate AM, et al. Serum amyloid a and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. Can J Cardiol 2012;28:537-41.
11. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A, et al. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol 2006;97:659-61. (Pubitemid 43255035)
12. Henningsen KM, Therkelsen SK, Bruunsgaard H, et al. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest 2009;69:425-32.
13. Liu J, Fang PH, Dibs S, et al. High-sensitivity C-reactive protein as a predictor of atrial fibrillation recurrence after primary circumferential pulmonary vein isolation. Pacing Clin Electrophysiol 2011;34:398-406.
14. Lombardi F, Tundo F, Belletti S, et al. C-reactive protein but not atrial dysfunction predicts recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. J Cardiovasc Med (Hagerstown) 2008;9:581-8. (Pubitemid 351677698)
15. Loricchio ML, Cianfrocca C, Pasceri V, et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2007;99:1421 -4.
16. Wazni O, Martin DO, Marrouche NF, et al. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 2005;91:1303-5. (Pubitemid 41360947)
17. Rizos I, Rigopoulos AG, Kalogeropoulos AS, et al. Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence. J Hum Hypertens 2010;24:447-57.
18. Watanabe E, Arakawa T, Uchiyama T, et al. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006;108:346-53. (Pubitemid 43339801)
19. Zarauza J, Rodriguez Lera MJ, Farinas Alvarez C, et al. Relationship between C-reactive protein level and early recurrence of atrial fibrillation after electrical cardioversion. Rev Esp Cardiol 2006;59:125-9.
20. Leeflang MM, Deeks JJ, Gatsonis C, et al. Systematic reviews of diagnostic test accuracy. Ann Intern Med 2008;149:889-97.
21. Arends LR, Hamza TH, van Houwelingen JC, et al. Bivariate random effects meta-analysis of ROC curves. Med Decis Making 2008;28:621-38.
22. Harbord RM,Whiting P, Sterne JA, et al. An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol 2008;61:1095-103.
23. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. (Pubitemid 37088507)
24. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. (Pubitemid 27387172)
25. Buob A, Jung J, Siaplaouras S, et al. Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol 2006;29:559-63. (Pubitemid 43886605)
26. Cosgrave J, Foley JB, Bahadur K, et al. Inflammatory markers are not associated with outcomes following elective external cardioversion. Int J Cardiol 2006;110:373-7. (Pubitemid 43841907)
27. Ellinor PT, Low A, Patton KK, et al. C-Reactive protein in lone atrial fibrillation. Am J Cardiol 2006;97:1346-50.
28. Korantzopoulos P, Kolettis TM, Kountouris E, et al. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation. Is there an association with early recurrence rates? Int J Clin Pract 2005;59:881 -5.
29. Psychari SN, Chatzopoulos D, Iliodromitis EK, et al. C-reactive protein, interleukin 6, and N-terminal pro-brain natriuretic peptide following cardioversion of atrial fibrillation: is there a role of biomarkers in arrhythmia recurrence? Angiology 2011;62:310-16.
30. Komatsu T, Sato Y, Ozawa M, et al. Relationship between CHADS2 score and efficacy of antiarrhythmic drug therapy in patients with paroxysmal atrial fibrillation. Circ J 2013;77:639-45.
31. Letsas KP, Efremidis M, Giannopoulos G, et al. CHADS2 and CHA2DS2-VASc scores as predictors of left atrial ablation outcomes for paroxysmal atrial fibrillation. Europace 2014;16:202-7.
32. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105:2595-9. (Pubitemid 34596034)
33. Parekh RS, Plantinga LC, Kao WH, et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int 2008;74:1335-42.
34. Streitner F, Kuschyk J, Veltmann C, et al. Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm. Cytokine 2009;47:166-72.
35. Korngold EC, Januzzi JL Jr, Gantzer ML, et al. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation 2009;119:2868-76.
36. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083-92. (Pubitemid 41408600)
37. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002;54:230-46. (Pubitemid 34327903)
38. Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 2008;52:306-13.
39. Moro C, Hernandez-Madrid A, Matia R. Non-antiarrhythmic drugs to prevent atrial fibrillation. Am J Cardiovasc Drugs 2010;10:165-73.
40. den Uijl DW, Delgado V, Tops LF, et al. Natriuretic peptide levels predict recurrence of atrial fibrillation after radiofrequency catheter ablation. Am Heart J 2011;161:197-203.
41. Tang Y, Yang H, Qiu J. Relationship between brain natriuretic peptide and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Int Med Res 2011;39:1618-24.